Darunavir: all 96 studies that test it

Page 1 of 1. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.

• An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingNCT07792096Phase 3
• Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingNCT07678268Phase 4
• A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingNCT06337032Phase 4
• Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected AdultsCompletedNCT02603107Phase 3Results posted
• HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedNCT02437110Phase 1Results posted
• A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsCompletedNCT02431247Phase 3Results posted
• Study Assessing the Effects of Darunavir/Ritonavir or Lopinavir/Ritonavir on the Pharmacokinetics of Daclatasvir in Healthy ParticipantsCompletedNCT02159352Phase 1Results posted
• Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDSCompletedNCT02155101Phase 3Results posted
• Phase 3 Open-Label Study to Evaluate Switching From Optimized Stable Antiretroviral Regimens Containing Darunavir to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) Plus Darunavir (DRV) in Treatment Experienced HIV-1 Positive AdultsCompletedNCT01968551Phase 3Results posted
• Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or EfavirenzCompletedNCT01695954Phase 1Results posted
• A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral FailureCompletedNCT01641367Phase 4Results posted
• A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current TreatmentCompletedNCT01448707Phase 3Results posted
• Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected AdultsCompletedNCT01440569Phase 3Results posted
• Effect of Multiple Dosing With BI 201335 on the Pharmacokinetics of Darunavir Co-administered With Ritonavir in Healthy Male and Female VolunteersCompletedNCT01374802Phase 1Results posted
• Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentCompletedNCT01363011Phase 3Results posted
• The Maraviroc Darunavir/Ritonavir Once Daily Pharmacokinetic StudyCompletedNCT01348763Phase 1Results posted
• TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVCompletedNCT01281813Phase 3Results posted
• A Study of the Once Daily Combination of Etravirine and Darunavir/Ritonavir As Dual Therapy in Early Treatment-Experienced PatientsCompletedNCT01199939Phase 2Results posted
• Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1CompletedNCT00993148Phase 2Results posted
• Evaluation of Three Strategies of Second-line Antiretroviral Treatment in Africa (Dakar - Bobo-Dioulasso - Yaoundé)CompletedNCT00928187Phase 3Results posted
• A Safety Study to Evaluate the Antiviral Activity of Darunavir in Combination With Ritonavir in HIV 1 Infected ChildrenCompletedNCT00919854Phase 2Results posted
• A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected AdolescentsCompletedNCT00915655Phase 2Results posted
• HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and EtravirineTerminatedNCT00855413Phase 4Results posted
• A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant WomenCompletedNCT00855335Phase 3Results posted
• Comparative Study of Three NNRTI-Sparing HAART RegimensCompletedNCT00811954Phase 3Results posted
• Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received TreatmentCompletedNCT00757783Phase 4Results posted
• Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and PravastatinCompletedNCT00630734Phase 4Results posted
• Optimizing Treatment for Treatment-Experienced, HIV-Infected PeopleCompletedNCT00537394Phase 3Results posted
• A Study to Evaluate the Pharmacokinetic Profile (How the Body Absorbs, Distributes, Metabolizes and Eliminates a Drug) of TMC125 Plus Tenofovir/Emtricitabine Once Daily With or Without Darunavir/r Once Daily in Antiretroviral (ARV) Naive HIV-1 Patients (Patients Have Never Received ARV Treatment).CompletedNCT00534352Phase 2Results posted
• A Study to Compare Effectiveness and Safety of Darunavir/Ritonavir (DRV/Rtv) 800mg/100mg Once Daily Versus DRV/Rtv 600mg/100mg Twice Daily in Early Treatment-Experienced HIV-1 Infected Patients (ODIN)CompletedNCT00524368Phase 3Results posted
• Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PITerminatedNCT00517192Phase 3Results posted
• Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.CompletedNCT00460746Phase 3Results posted
• Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/RitonavirCompletedNCT00458302Phase 3Results posted
• GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.CompletedNCT00381303Phase 3Results posted
• A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy ParticipantsCompletedNCT05378906Phase 1
• A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed ConditionsCompletedNCT04718805Phase 1
• A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate AgentsCompletedNCT04661397Phase 1
• Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)CompletedNCT04388904Phase 4
• Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)CompletedNCT04268472Not applicable
• Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19Status unknownNCT04252274Phase 3
• A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat When Administered as a Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared to the Co-administration of the Separate AgentsTerminatedNCT04236453Phase 1
• A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy ParticipantsCompletedNCT04208061Phase 1
• Inflammation and Co-Infections in D²EFTWithdrawnNCT04183738Phase 4
• RPV+DRV/Cobi Dual Therapy in Subjects With HIV Controlled InfectionStatus unknownNCT04064632Phase 4
• Nucleosides And Darunavir/Dolutegravir In AfricaStatus unknownNCT03988452Phase 3
• Body Composition Sub-study of the D2EFT TrialCompletedNCT03675815Phase 4
• Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive ImplantStatus unknownNCT03589040Phase 2
• Darunavir and Rilpivirine Interactions With Levonorgestrel ImplantStatus unknownNCT03589027Phase 2
• Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)TerminatedNCT03163277Phase 4
• Optimization of Darunavir Therapy and Dosage RecommendationsCompletedNCT03101644Phase 4
• The Pharmacokinetics of Dolutegravir, Darunavir/Cobocistat When Co-administered in Healthy VolunteersCompletedNCT03094507Phase 1
• Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownNCT03017872Phase 4
• Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult ParticipantsCompletedNCT02984852Phase 1
• Evaluation of Low-dose Darunavir in a Switch StudyCompletedNCT02671383Phase 3
• SSAT067 PK of Atazanavir/Cobicistat and Darunavir/CobicistatCompletedNCT02589158Phase 1
• A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsCompletedNCT02578550Phase 1
• Effect of Cobicistat Versus Ritonavir Boosting on the Brain Permeation of Darunavir in HIV-infected IndividualsTerminatedNCT02503462Phase 4
• Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500CompletedNCT02489487Phase 1
• Relative Bioavailability and Food Effect for Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Fixed Dose CombinationCompletedNCT02475135Phase 1
• Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 PatientsCompletedNCT02384967Phase 2
• A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)CompletedNCT02277600Phase 1
• A Study to Assess the Long-term Safety and Tolerability of TMC114/Rtv in HIV-1 Infected Participants After Rolling-over From Other TMC114 TrialsCompletedNCT02187107Phase 2
• DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)CompletedNCT02063360Phase 1
• Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingNCT02016924Phase 2/3
• Evaluation of the Efficacy and Safety Between Two Antiretroviral Regimens, in HIV-1-infected Treatment-naïve Subjects With Low CD4 CountsCompletedNCT01928407Phase 4
• A Phase 4 Study to Evaluate Pharmacokinetics and Safety of Darunavir Along With Ritonavir in Healthy Male Japanese ParticipantsCompletedNCT01810887Phase 4
• A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.CompletedNCT01736761Phase 4
• Early Access to Low-dose Ritonavir (TMC114/r) and Other Antiretrovirals (ARVs) for Treatment-naive or Early Treatment Experienced in HIV-1 PatientsCompletedNCT01702090Phase 4
• A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted ConditionsCompletedNCT01619527Phase 1
• Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneWithdrawnNCT01605084Phase 3
• A Study of Drug-Drug Interaction Between Darunavir and Danoprevir Administered Together With Low-Dose Ritonavir in Healthy VolunteersCompletedNCT01519336Phase 1
• TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)CompletedNCT01323257Phase 1
• TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted ConditionsCompletedNCT01308658Phase 1
• Metabolic Effects of Atazanavir/Ritonavir Versus Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine in naïve HIV-1 Infected PatientsCompletedNCT01274780Phase 4
• TMC114-TiDP29-C232 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Children Coming From Any of the Three Ongoing Tibotec Sponsored Pediatric Studies With DRVCompletedNCT01138605Phase 2
• The First Failure StudyTerminatedNCT01118871Phase 4
• Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected SubjectsCompletedNCT01047995Phase 1
• Optimisation of Primary HIV1 Infection Treatment(ANRS 147 OPTIPRIM)CompletedNCT01033760Phase 3
• TMC114-C201: A Study to Determine the Antiviral Activity of TMC114 in Patients With Multiple Protease Inhibitor (PI) Resistant Human Immunodeficiency Virus (HIV) StrainsCompletedNCT00964327Phase 2
• GSK1349572 Drug Interaction With Etravirine and Either Darunavir/Ritonavir or Lopinavir/RitonavirCompletedNCT00867152Phase 1
• Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal TissueCompletedNCT00855088Phase 1
• Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629CompletedNCT00854204Phase 1
• Study of Protease Inhibitor Regimen Switch in HIV-1 Infected Patients With Undetectable Viral Load to Prove the Non-inferiority of Once Daily Dose Regimen Versus the Current Twice Daily Regimen to Maintain the Viral Load Under the Limit of Detection.CompletedNCT00849160Phase 3
• A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult SubjectsCompletedNCT00783484Phase 1
• VX-950-TiDP24-C124: A Phase I Trial to Investigate the Potential Pharmacokinetic Interactions Between Telaprevir and Darunavir/Ritonavir and Between Telaprevir and Fosamprenavir/Ritonavir at Steady-state.CompletedNCT00775125Phase 1
• NNRTI/PI Toxicity Switch to Darunavir StudyTerminatedNCT00765154Phase 4
• TMC114-TiDP29-C169: Bioavailability and Pharmacokinetics Trial Comparing Darunavir Pediatric Suspension Formulation to Current Darunavir TabletCompletedNCT00752310Phase 1
• TMC114-TiDP3-C181: Study to Assess the Pharmacokinetics of Darunavir (DRV) With Different Doses of Ritonavir in Healthy Volunteers.CompletedNCT00744887Phase 1
• TMC114-C213: A Phase II Randomized, Controlled, Partially Blinded Trial to Investigate Dose-response of TMC114/RTV in 3-class-experienced HIV-1 Infected Patients, Followed by an Open-label Period on the Recommended Dose of TMC114/RTV.CompletedNCT00650832Phase 2
• Evaluate the Efficacy and Security of Darunavir/Ritonavir 900/100 mg Once a Day as an Antiretroviral Treatment Simplification StrategyCompletedNCT00611039Phase 4
• TMC114-C227: A Study to Evaluate the Effectiveness and Safety of TMC114 (Darunavir) With a Low Dose of Ritonavir as Monotherapy (no Other Anti-HIV Drugs Will be Given) in Patients Who Have Never Been Treated With Antiretrovirals (Anti-HIV Drugs) PreviouslyTerminatedNCT00513513Phase 2
• Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136CompletedNCT00421551Phase 3
• A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and AdolescentsCompletedNCT00355524Phase 2
• Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected ChildrenCompletedNCT00260078Phase 1/2
• TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment OptionsCompletedNCT00115050Phase 3
• An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.CompletedNCT00081588Phase 2

← Darunavir overview